Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 3

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 6Lymphoid 5Gynecologic 5Other solid neoplasm 4Head & Neck 4Genitourinary 4Other hematologic neoplasm 3Breast 3Thoracic 2Dermatologic 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 3Camurati-Engelmann Syndrome 1

Interventions

Trastuzumab 692Paclitaxel 678Cyclophosphamide 634Docetaxel 553Capecitabine 467Letrozole 407Carboplatin 392Fulvestrant 377Doxorubicin 330Tamoxifen 288pembrolizumab 270Anastrozole 252Epirubicin 249exemestane 238pertuzumab 226Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 117

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Fenretinide × Breast × Clear all
NCT00003099 2012-07-30

Chemoprevention Therapy Plus Surgery in Treating Women With Breast Cancer

M.D. Anderson Cancer Center

Phase 2 Completed
52 enrolled
Breast

Breast Neoplasms

NCT00002646 2012-01-05

Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer

National Cancer Institute (NCI)

Phase 3 Completed
1,500 enrolled
Breast

Breast Neoplasms

NCT00001378 2008-03-04

A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
75 enrolled
Breast

Breast Neoplasms, Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡